Re­gen­er­a­tive cell biotech Thym­mune launch­es with back­ing from George Church, John Maraganore

Thym­mune Ther­a­peu­tics is go­ing af­ter “the most im­por­tant or­gan you’ve nev­er heard of,” ac­cord­ing to Pil­lar VC’s Thomas de Vlaam.

The Cam­bridge, MA-based biotech has raised $7 mil­lion in seed fund­ing to push its thymic cell ther­a­py through pre­clin­i­cal stud­ies, it an­nounced Wednes­day. Thym­mune was found­ed in 2019 by famed Har­vard ge­neti­cist George Church’s lab alum­ni Stan Wang, who is al­so the biotech’s CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER